First, last, corresponding authors

This is a list of publications with cancer center members as either first, last, or corresponding author arranged by highest impact factor.

Scott AJ, Kennedy EB, Gholami S. Reply to: Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer? J Clin Oncol. March 10, 2025;:JCO2402435. Impact factor: 44.5

Yang J, Lim JT, Santiago Raj PV, Corona MG, Chen C, Khawaja H, Pan Q, Paine-Murrieta GD, Schnellmann RG, Roe DJ, Gokhale PC, DeCaprio JA, Padi M. Integrative analysis reveals therapeutic potential of pyrvinium pamoate in Merkel cell carcinoma. J Clin Invest. Feb. 11, 2025; Impact factor: 14.8

Mesgarzadeh S, Myrdal CN, Gong AH, Stratton DB, Kelly BG, Curiel-Lewandrowski C. Heterogeneity among melanoma databases and challenges in sustainability: A survey of the Melanoma Prevention Working Group. JAAD Int. 2025;18:137-139. PMCID: PMC11697841. Feb. 1, 2025. Impact factor: 12.8

Clements AN, Casillas AL, Flores CE, Liou H, Toth RK, Chauhan SS, Sutterby K, Deshmukh SK, Wu S, Xiu J, Farrell A, Radovich M, Nabhan C, Heath EI, McKay RR, Subah N, Centuori S,  Wheeler TJ, Cress AE, Rogers GC, Wilson JE, Recio-Boiles A, Warfel NA. Inhibition of PIM kinase in tumor-associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy. Cancer Immunol Res. Feb. 21, 2025;. Impact factor: 12

Carew JS, Espitia CM, Sureshkumar S, Carrera Espinoza MJ, Gamble ME, Wang W, Lee BR, Nawrocki ST. REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM activity. Cancer Lett. 2025;:217496. Impact factor: 9.7

Smith KA, Batatinha H, Niemiro GM, Baker FL, Zúñiga TM, Diak D, Mylabathula PL, Kistner TM, Davini D, Hoffman E, Colombo JN, Seckeler M, Bond RA, Katsanis E, Simpson RJ. Exercise-induced β(2)-adrenergic receptor activation enhances effector lymphocyte mobilization in humans and suppresses lymphoma growth in mice through NK-cells. Brain Behav Immun. 2025 Apr 29;. doi: 10.1016/j.bbi.2025.04.040. [Epub ahead of print] PubMed PMID: 40311885. Impact factor: 8.8

Bernardazzi C, Saha T, Gurney MA, Laubitz D, Dey PD, Masannat T, Sheikh IA, Midura-Kiela MT, Ghishan FK, Kiela PR. NHE3 Controls Proliferation and Migration of Colonic Epithelial Cells. Inflamm Bowel Dis. Feb. 17, 2025;. Impact factor: 7.3

Baker FL, SJ, Cracchiolo MJ, Davini D, Simpson RJ., Katsanis E. Impact of post-transplant cyclophosphamide with bendamustine on immune reconstitution in young patients undergoing T-cell replete haploidentical bone marrow transplantation: results from a phase Ia/Ib clinical trial. Frontiers in Immunology. April 8, 2025; 16. Impact factor: 5.7

Barker K, Marco T, Husnain M, Katsanis E. Addition of Phosphorous and IL6 to m-EASIX Score Improves Detection of ICANS and CRS, as Well as CRS Progression. Cancers. 2025; 17(6):918.  Impact factor: 5.2

Allen AM, Cao Q, Stayer LG, Luo X, Jensen J, Pang RD, Allen S, Donny EC, Benowitz N, Smith T,  Hatsukami D. Differences in Combustible Cigarette Smoking-Related Biomarkers by Hormonal Contraceptive Use: An Exploratory Study. Nicotine Tob Res. Jan. 30, 2025;. Impact factor: 4.2

Rocha AD, Long DJ, Drake WK, Galvez DB, Rice PF, Reed MN, Heusinkveld JM, Barton JK.  First Clinical Feasibility and Safety Study of a Novel Multimodality Fallopian Tube Imaging Endoscope. Lasers Surg Med. Feb. 1, 2025; Impact factor: 4

Alsowaida YS, Alsolami A, Almangour TA, Abraham I. Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA Adverse Events Reporting System (FAERS). Expert Opin Drug Saf. Feb. 1, 2025;. Impact factor: 4

Harel K, Czamanski-Cohen J, Cohen M, Caspi O, Weihs KL. Coping, Emotional Processing, and Cancer-Related Symptoms in Breast Cancer Survivors: Cross-Sectional Secondary Analysis of the REPAT Study. Psychooncology. 2025;34(2):e70094. Feb. 1, 2025 PMCID: PMC11785827. Impact factor: 3.9

Goodrich JM, Furlong MA, Urwin DJ, Gabriel J, Hughes J, Jung AM, Calkins MM, DuBose KN, Caban-Martinez AJ, Solle NS, Beitel SC, Burgess JL (CPCP). Epigenetic Modifications Associated With Wildland-Urban Interface (WUI) Firefighting. Environ Mol Mutagen. Jan. 1, 2025;. PMCID: PMC11905879. Impact factor: 3.6 

Fox RS, Brandon K, Badger TA, Gaumond JS, Morales AA, Ong JC, Parthasarathy S, Rini C, Zee PC,  Tanner EJ, Ancoli-Israel S, Penedo FJ, Siddique J,  Wu LM,  Reid KJ, Kaiser K. Stakeholder-informed refinement of a behavioral sleep/circadian intervention for gynecologic cancer survivors: an application of the MOST preparation phase. Transl Behav Med. 2025;15(1). PMCID: PMC11795304. Impact factor: 3.6

Galouzis N, Khawam M, Alexander EV, Mesropyan L, Luu C, Khreiss MR, Riall TS. Quality of Life and Social Health in Patients After Pancreatic Surgery. J Gastrointest Surg. March 1, 2025;:101969. Impact factor: 3.5

Bea JW, Ochs-Balcom HM, Valencia CI, Chen Z, Blew RM, Lind KE, Caan BJ, Roe DJ, Rohan TE, Reeves KW,  Manson JE, Ballinger T, Reding KW,  Follis S, Ziller SG, Odegaard AO. Abdominal visceral and subcutaneous adipose tissue associations with postmenopausal breast cancer incidence. JNCI Cancer Spectr. 2025;. PMCID: PMC11879126. Impact factor: 3.4

Segrin C, Sikorskii A, Cunicelli N, Badger T. Moderators of interdependent psychological distress in cancer survivor-caregiver dyads. J Psychosoc Oncol. Jan. 9, 2025:1-19. Impact factor: 2.6

Harris HR, Lind K, Fest S, Thomson CA, Saquib N, Shadyab AH, Schnatz PF, Robles-Morales R, Qi L, Strickler HD, Roe DJ, Farland LV. Infertility and risk of ovarian cancer in the women's health initiative. Cancer Causes Control. Jan. 29, 2025;. Impact factor: 2.5

Collaborators

List of cancer center members who were listed on a publication, but were not first, last or corresponding author.

Knox JJ,  McNamara MG,  Bazin IS, Oh DY,  Zubkov O, Breder V, Bai LY, Christie A, Goyal L, Cosgrove DP, Springfeld C, Sjoquist KM,  Oh Park J, Verdaguer H, Braconi C, Ross PJ, De Gramont A, Shroff RT, Zalcberg JR, Palmer DH, Smith JR, Oelmann E,  Bruce T, Valle JW. A phase III randomised study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer. J Hepatol. Feb. 18, 2025;. Impact factor: 30

Buchanan C, Karunanithy G, Tkachenko O, Barber M, Marty MT,  Nott TJ, Redfield C,  Baldwin AJ. Unidec NMR: automatic peak detection for NMR spectra in 1-4 dimensions. Nat Commun. Jan 7, 2025;16(1):449. PMCID: PMC11707349. Impact factor: 17.7

Palczewski MB,  Kuschman HP, Hoffman BM,  Kathiresan V,  Yang H, Glynn SA, Wilson DL, Kool ET, Montfort WR, Chang J, Petenkaya A, Chronis C, Cundari TR, Sappa S, Islam K,   McVicar DW,  Fan Y, Chen Q, Meerzaman D, Sierk M, Thomas DD. Nitric oxide inhibits ten-eleven translocation DNA demethylases to regulate 5mC and 5hmC across the genome. Nat Commun. Feb. 18, 2025;16(1):1732. PMCID: PMC11836389. Impact factor: 17.7

Roland-McGowan JN, Freeman SC, Baghoomian W, Carroll BT, Kim CC, Curiel-Lewandrowski C, Chu EY,  Foster EL,  Nelson KC, White KP,  Ming ME,  Hartman RI, Leachman SA,  Mengden-Koon S, Chen SC, Swetter SM, Prieto VG,  Berry E, Yu WY. Development of a Treatment Decision Aid for Patients with Dysplastic Nevi Who Are Candidates for Re-Excision. J Am Acad Dermatol. Jan. 7, 2025; Impact factor: 15.5

Nascimento de Lima P, Matrajt L, Coronado G,  Escaron AL, Rutter CM. Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics. JAMA Netw Open. 2025;8(1):e2454938. Jan. 1, 2025;. PMCID: PMC11739995. Impact factor: 13.3

Ardalan B, Ciner A, Baca Y, Hinton A, Darabi S, Kasi A, Lou E, Azqueta JI, Xiu J, Datta J,  Shields AF, Aguirre A, Singh H, Shroff RT, Pishvaian MJ, Goel S. Distinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinoma. Clin Cancer Res. March 17, 2025;. Impact factor: 12.5

Juetten KJ, Sanders JD, Marty MT, Brodbelt JS. Combining Fourier Transform Ion Mobility with Charge Detection Mass Spectrometry for the Analysis of Multimeric Protein Complexes. Anal Chem. Jan. 14, 2025;97(1):140-146. Impact factor: 8

Gutmair K, Villa D, Cunningham N,  Silkenstedt E,  Rimsza LM,  Ramsower CA, Scott DW, Gerrie AS, Kluin-Nelemans HC, Dreyling M,  Hoster E. BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma. Blood Adv. Feb. 21,2025;. Impact factor: 7.6

Marcotte LM,  Khor S,  Reddy A,   Morenz A,  Nelson K,  Akinsoto N, Lee ES,  Onstad S, Wong ES. An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system. Cancer. Feb. 1, 2025;131(3):e35734. Impact factor: 6.9

Chung V, Alistar A, Becerra C, Kasi A, Borazanci E,  Jameson GS, Roe DJ, Wertheim BC,  Cridebring D, Truitt M, Downes M,  Barrett MT, Korn R,  Lee K, Han H, Evans R, Von Hoff DD. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Oncologist. 2025;30(1). PMCID: PMC11756276. Impact factor: 5.8

Deressa BT, Pierz A, Jyung H, Rosario B, Andoh-B-Baidoo N, Tibebu B,  Seife E, Bekele E, Hussein R,  Gedif T, Madhivanan P, Lott B. A qualitative study on the psycho-oncological experiences of women navigating breast cancer diagnosis, treatment, and survivorship in Ethiopia. J Cancer Surviv. Feb. 8,2025;. Impact factor: 4.4

Zhao YJ, Zhang SY, Wei YY,  Li HH,  Lei W, Wang K, Kumar S, Zhou C, Zheng J. An Endogenous Aryl Hydrocarbon Receptor Ligand Dysregulates Endothelial Functions, Transcriptome, and Phosphoproteome. Am J Physiol Cell Physiol. March 1, 2025. Impact factor: 4.2

Weinfeld-Yehoudayan A, Czamanski-Cohen J, Weihs KL, Cohen M. Using Drawings to Measure Emotional Processing in Breast Cancer Survivors and Its Association With Depression, Pain, and Fatigue. Psychooncology. 2025;34(2):e70099. PMCID: PMC11813831. Impact factor: 3.9

Domanico MC, Collette NM, Ubick E, Ding X,  Buchholz BA, Van Winkle LS. DNA adducts form in mouse lung and liver after oral naphthalene exposure. Toxicol Sci. Feb. 8, 2025;. Impact factor: 3.8

Hagio T, Galons JP,  Roe D, Marron MT, Thomson C, Thompson P, Stopeck AT, Bilgin A, Altbach MI, Chiang JA. Concurrent water T(2) and fat fraction mapping of the breast using the radial gradient and spin echo (RADGRASE) pulse sequence. Magn Reson Imaging. Feb. 1, 2025;:110355. Impact factor: 3.1

Warner EL, Sikorskii A, Cunicelli N, Badger T, Segrin C, Morrill KE, Rainbow J. Employment productivity and cancer-related psychological symptoms among adult cancer dyads. J Occup Environ Med. Jan. 30, 2025;. Impact factor: 2.3

Ko AH, Chao J, Noel MS, Shankaran V, Sohal D, Crow M, Oberstein PE, Scott AJ, McRee AJ, Rocha Lima CMSP,  Fong L, Keenan BP, Soto M, Filbert EL, Hsu FJ, Yang X. A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, Plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers. Cancer Res Commun. 2025;. PMCID: PMC11843624. Impact factor: 2

Carson WO, Little A, Monetathchi A, Erdrich J, Cordova-Marks FM. Analysis of Urban Indian Organizations' Promotion of Cancer Services. Cancer Res Commun. Feb. 1, 2025;. PMCID: PMC11863186. Impact factor: 2

Tseng HW, Vedantham S, Fu Z. Simultaneous Reduction of Radiation Dose and Scatter-to-Primary Ratio using a Truncated Detector and Advanced Algorithms for Dedicated Cone-Beam Breast CT. Biomed Phys Eng Express. March 3, 2025;. Impact factor: 1.3